← Back to All US Stocks

BNTX Stock Analysis - BioNTech SE AI Rating

BNTX Nasdaq Biological Products, (No Diagnostic Substances) 2M CIK: 0001776985
Recently Updated • Analysis: Mar 21, 2026 • SEC Data: 2026-03-21
AI Rating
HOLD
5% Confidence

📊 BNTX Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence

Investment Thesis

Unable to provide meaningful fundamental analysis due to complete absence of financial data. All key metrics including revenue, profitability, balance sheet items, and cash flow are unavailable, preventing assessment of financial health or operational performance.

BNTX Strengths

  • -No strengths identified

BNTX Risks

  • ! No financial data available for analysis
  • ! Inability to assess profitability or operational efficiency
  • ! No visibility into balance sheet strength or liquidity position
  • ! Cannot evaluate cash generation or capital allocation
  • ! Zero insider trading activity in last 90 days suggests no recent insider conviction

Key Metrics to Watch

BNTX Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BNTX Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

BNTX vs Healthcare Sector

How BioNTech SE compares to Healthcare sector averages

Net Margin
BNTX 0.0%
vs
Sector Avg 12.0%
BNTX Sector
ROE
BNTX 0.0%
vs
Sector Avg 15.0%
BNTX Sector
Current Ratio
BNTX 0.0x
vs
Sector Avg 2.0x
BNTX Sector
Debt/Equity
BNTX 0.0x
vs
Sector Avg 0.6x
BNTX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

BNTX Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

BNTX Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BNTX SEC Filings

Access official SEC EDGAR filings for BioNTech SE (CIK: 0001776985)

📋 Recent SEC Filings

Date Form Document Action
Feb 21, 2024 SC 13D d782522dsc13d.htm View →
Feb 14, 2020 SC 13G d909087dsc13g.htm View →
Feb 13, 2020 SC 13G d835876dsc13g.htm View →
Feb 12, 2020 SC 13G d878301dsc13g.htm View →
Jan 23, 2020 SC 13D d875408dsc13d.htm View →

Frequently Asked Questions about BNTX

What is the AI rating for BNTX?

BioNTech SE (BNTX) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are BNTX's key strengths?

.

What are the risks of investing in BNTX?

No financial data available for analysis. Inability to assess profitability or operational efficiency.

What is BNTX's revenue and growth?

BioNTech SE reported revenue of N/A.

Does BNTX pay dividends?

BioNTech SE does not currently pay dividends.

Where can I find BNTX SEC filings?

Official SEC filings for BioNTech SE (CIK: 0001776985) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BNTX's EPS?

BioNTech SE has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 21, 2026 | Data as of: 2026-03-21 | Powered by Claude AI